Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Monoclonal Antibodies

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

The ZEUS result challenges whether IL‑6 suppression will deliver patient‑level cardiovascular benefit and creates safety and commercial questions for the program.

3 ARTICLES

4mo ago

FDA Grants Priority Review to Roche’s Enspryng for Thyroid Eye Disease

3 ARTICLES

6mo ago

AstraZeneca’s Tozorakimab Hits Phase III Goal in COPD, Marking Third Positive Pivotal Trial

4 ARTICLES

7mo ago

Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

4 ARTICLES

9mo ago

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

4 ARTICLES

9mo ago

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

5 ARTICLES

10mo ago

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

4 ARTICLES

10mo ago

FDA Approves Amgen’s Uplinza for Generalized Myasthenia Gravis

8 ARTICLES

last yr.

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case

4 ARTICLES

last yr.

BioCryst to Acquire Astria in $700 Million Cash-and-Stock Deal to Bolster HAE Portfolio

4 ARTICLES

last yr.

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

3 ARTICLES

last yr.

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

3 ARTICLES

last yr.

One in Three Infants Received Preventive RSV Antibody in First Season, Study Finds